James Porile, MD
Nephrology · Mishawaka, INNPI 1922008796
Payments from drug & device makers
Across 136 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$534
- Vifor Pharma, Inc.$318
- Otsuka America Pharmaceutical, Inc.$316
- Bayer$241
- Fresenius USA Marketing, Inc.$231
- Nxstage Medical, Inc.$181
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,191100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 27 | $534 |
| Vifor Pharma, Inc. | 13 | $318 |
| Otsuka America Pharmaceutical, Inc. | 13 | $316 |
| Bayer | 11 | $241 |
| Fresenius USA Marketing, Inc. | 14 | $231 |
| Nxstage Medical, Inc. | 3 | $181 |
| Amgen | 8 | $154 |
| Mallinckrodt Enterprises LLC | 2 | $133 |
| Calliditas Therapeutics US Inc. | 6 | $128 |
| Mallinckrodt Hospital Products Inc. | 5 | $111 |
| OPKO Pharmaceuticals, LLC | 5 | $109 |
| Abbott | 1 | $96 |
| Travere Therapeutics, Inc. | 5 | $94 |
| Bard Peripheral Vascular, Inc. | 1 | $86 |
| Novartis | 3 | $70 |
| Aurinia Pharma U.S., Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $49 |
| Baxter Healthcare | 1 | $47 |
| GSK | 3 | $40 |
| Lilly USA, LLC | 2 | $40 |
| Cormedix Inc. | 1 | $26 |
| Novo Nordisk | 1 | $26 |
| Ardelyx, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Akebia Therapeutics Inc | 1 | $21 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$125
How this compares
$3,198 in reported general payments places this provider in the 70th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 253 | $216,026 |
| VelphoroSucroferric Oxyhydroxide | 57 | $174,317 |
| AuryxiaFerric Citrate | 26 | $53,730 |
| XphozahTenapanor Hcl | 14 | $50,656 |
| KerendiaFinerenone | 60 | $50,058 |
| VeltassaPatiromer Calcium Sorbitex | 37 | $42,531 |
| Sevelamer Carbonate | 118 | $25,291 |
| Lanthanum Carbonate | 19 | $10,931 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,365 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,033 |
| Potassium Citrate ErPotassium Citrate | 32 | $4,556 |
| Midodrine Hcl | 28 | $2,908 |
| Chlorthalidone | 175 | $2,776 |
| Losartan Potassium | 277 | $2,113 |
| Spironolactone | 184 | $1,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $534 | $226,391269 claims |
| Fresenius USA Marketing, Inc.Velphoro | $231 | $174,31757 claims |
| Akebia Therapeutics IncAuryxia | $21 | $53,73026 claims |
| BayerKerendia | $241 | $50,05860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 238 nephrology providers in Indiana.
Other nephrology in Mishawaka
- Sudhir VyakaranamMishawaka$258K
- Lily SunioMishawaka$4K
- Henry WuMishawaka$4K
- Andrew OshaughnessyFort Wayne$1.2M
- Rajiv AgarwalIndianapolis$1.2M
- Garima GuptaFort Wayne$666K
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$471K
- Kenneth ChoiMerrillville$392K
- Arjun SinhaIndianapolis$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.